Phaseline

Companies › CytosinLab Therapeutics

CytosinLab Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CTS3497
MTAP inhibitor
MTAPPhase 1Solid TumorDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06971523CTS3497Phase 1Solid TumorOncologyDec 2028

Targets

MTAP (1)

Companies with the same targets

Bristol-Myers Squibb Gilead Sciences BeOne Medicines Heronova Pharmaceuticals Haisco Pharmaceutical Group Abbisko Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.